Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 28, 2014 (12 years ago)

Dermatend Original

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Labeling Bears Unapproved Claims; Dermatend is not FDA approved and therefore has not been shown to be safe and effective for the uses suggested in the labeling.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Dermatend Original, mole, wart and skin tag remover, For external use only, Ingredient: Distilled Water, Sanguinaria Canadensis, Vegetable Glycerin, Butter of Zinc, Germall Plus, 0.17 OZ (5g) container, Solace International, Inc., Reno, NV 89509, USA

Drug: Zinc

Recalling firm
Solace International Inc
Origin
NV, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1585-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Zinc recalls

See all
Class II · Moderate risk

Zicam

CGMP Deviations; FDA inspection of the contract manufacturer noted out of limit results for microbiological testing

Ongoing Microbial contamination Church & Dwight Co., Inc. D-0790-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0642-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0641-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0637-2026

Other recalls by Solace International Inc

All 2014 recalls
Class II · Moderate risk

Dermatend Ultra

Labeling: Labeling Bears Unapproved Claims; Dermatend is not FDA approved and therefore has not been shown to be safe and effective for the uses suggested in the labeling.

Terminated Labeling / mix-up Solace International Inc D-1586-2014